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Abstract
Health economic evaluation studies are widely used in public health to assess health
strategies in terms of their cost-effectiveness and inform public policies. We developed an
R package for writing Markov models for health economic evaluations which implements
the modelling and reporting features described in reference textbooks and guidelines: de-
terministic and probabilistic sensitivity analysis, heterogeneity analysis, time dependency
on state-time and model-time (semi-Markov and non-homogeneous Markov models), etc.
In this paper we illustrate the features of heemod by building and analysing an example
Markov model. We then explain the design and the underlying implementation of the
package.
Keywords: health economic evaluation, Markov models, R.
1. Introduction
Health economic evaluation studies are widely used in public health to assess healthcare
strategies in terms of their cost-effectiveness and inform public policies (Russell et al. 1996).
In order to account for the long-term consequences of healthcare strategies, models are needed
to extrapolate results to a longer time frame (Sonnenberg and Beck 1993; Eddy et al. 2012).1
These models estimate the repartition of a population in various health states (e.g. healthy,
sick, dead) and how its health is affected by different strategies. Costs (e.g. medical or drug
costs) and outcomes (e.g. life years or quality of life) are attached to each distinct health
status, allowing to estimate the cost and effectiveness expected for every studied strategy.
By representing health status as states and health changes over time as transitions prob-
abilities between states this process can be modelled with Markov chains, using a Markov
model. Transition probabilities between states can be described by a square 2-dimensional
transition matrix T , where element i, j is the transition probability between state i and j.
The probability of being in a given state at time t is given by:
X × T t (1)
1Usually the entire target population lifetime.
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2 heemod: Models For Health Economic Evaluation in R
Where X is a vector2 giving the probability of being in a given state at the start of the model,
and T t is the product of multiplying t matrices T . The use of Markov models in health
economic evaluation have been thoroughly described in Beck and Pauker (1983), Sonnenberg
and Beck (1993) and Briggs and Sculpher (1998).
In order to best inform the decision process, Markov models should incorporate a wide
range of information to account for all the available evidence at a given time (Briggs and
Sculpher 1998). Results from various sources can be combined, such as estimated drug effi-
cacy from clinical trials, disease evolution from epidemiological cohorts, quality of life values
from population-level studies, transition probabilities from life-tables, etc. An implementation
of Markov models should be flexible enough to receive all these sources of data.
Most Markov models are built using basic spreadsheet software such as Microsoft Excel (Mi-
crosoft Corp. 2016) or commercial packages such as TreeAge (TreeAge Software Inc. 2017),
which has drawbacks: analyses are hard to reproduce and lack transparency, errors are difficult
to spot, track and correct, and graphic capabilities are lacking (Williams et al. 2016a). The
R language (R Core Team 2016) can overcome these issues through script-based approaches:
there is a written record of what was done, the calculations are transparent, modification can
be easily applied to the model, traceability is guaranteed,3 and the code just needs to be run
again to reproduce the analysis (Williams et al. 2016a). Despite these advantages, usage of
R in health economic modelling has been limited by the significant challenge of programming
Markov models from scratch and the lack of packages providing a comprehensive set of tools
for developing such models.
Our objective was to develop an R package for writing Markov models for health economic
evaluations, using a simple declarative syntax, which implements the modelling and reporting
features described in reference textbooks (Drummond et al. 2005; Briggs et al. 2006) and
guidelines (Eddy et al. 2012; Husereau et al. 2013). We named the package heemod, standing
for Health Economic Evaluation MODelling. The package is available from the Comprehensive
R Archive Network (CRAN) at http://CRAN.R-project.org/package=heemod.
In Section 2 we illustrate the possibilities of heemod by building and analysing an example
Markov model. For completeness we then present in Section 3 the features that were not used
in the previous example. In Section 4 we detail the mathematical implementation of some
functionalities. Finally in Section 5 we explain the design and the back-end of the package.
2. Building and analysing a model: an example
In this section we use a simplified example to illustrate how and why Markov models are used
in health economic evaluation studies. We introduce theoretical concepts and methods along
as they are encountered, present the production of results with the heemod package, and their
interpretation. In this article we used heemod version 0.9.0.9001.
2.1. Description of the question
For this example we will model the imaginary disease called shame, which is still a terminal
disease in some parts of the Galaxy (Adams 1979). At the onset the disease is asymptomatic:
2Of length equal to the number of states.
3Especially with the help of version control software such as git (Torvalds and Hamano 2017) that are
particularly well suited to script files.
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patients are quite unashamed, they do not feel sick, have a good quality of life, and are not
likely to die of shame. But patients are at risk of being ashamed: that marks the entry into
the symptomatic phase of the disease, with frequent hospital stays, deteriorated quality of life
and a high risk of dying of shame. The probability to revert to the asymptomatic unashamed
state is unfortunately quite low, and there is no cure known to work reliably: to be effective
shame therapy should thus be provided during the initial asymptomatic state, to prevent
being ashamed in the first place.
2.2. Compared strategies
Three strategies are proposed to prevent being ashamed:
Base strategy (base): Do nothing, this is the natural evolution of the disease.
Medical treatment (med): Patients with asymptomatic disease are treated with a ashaminib,
a highly-potent shame inhibitor, until progression to symptomatic state in order to lower
the risk of being ashamed.
Surgical treatment (surg): Patients with asymptomatic disease undergo shamectomy, a
surgical procedure that lowers the risk of being ashamed. The procedure needs to be
performed only once.
Medical treatment is effective in preventing symptomatic disease, but the drug is expensive.
Surgical treatment is a one-time cost, but its effect decreases with time. The increased
probability of dying of shame once in the symptomatic disease state does not depend on the
treatment used before, when the disease was asymptomatic.
2.3. States
From the description of the disease we can define 3 states:
Asymptomatic state (pre): Before the symptomatic state, when treatment can still be
provided.
Symptomatic state (symp): Symptomatic disease, after being ashamed. With degraded
health, high hospital costs and increased probability of dying of shame.
Death (death): Death by natural causes or because of shame.
2.4. Model parameters
In this section we define parameters that will be called later in the analysis (e.g. in the
transition matrix or the state values). Because we said in the disease description that some
probabilities and values vary with time, we need to introduce some concepts regarding time-
dependency before we can define the parameters.
Transition probabilities or state values may change with time (e.g. the protecting effect
of surgery may decrease with time after the procedure, probability of all-causes death may
increase as the population gets older, hospital costs may change with disease evolution). It is
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thus important to account for time-dependency in order to build accurate models. In Markov
models values may depend on 2 distinct measurements of time (Hawkins et al. 2005): time
elapsed since the start of the model (called model time), and time spent in a given state
(called state time). Both situations can co-exist in a same model.
In heemod time-dependency is specified with 2 variables: model_time4 and state_time.
These package-reserved names return sequential values starting from 1, corresponding to
time spent in the model for model time and time spent in a given state for state time. They
can be used in any user-defined expression or function.
In our case the probability of all-cause death depends on age. Because age increases with time
spent since the beginning of the model, the all-cause death probability is model time depen-
dent. On the other hand the probability of dying of shame depends on the time elapsed after
being ashamed (i.e. time spent in the symp state): this probability is state time dependent.
The probability of being ashamed after surgery, the cost of surgery, and the hospital costs in
the symptomatic state also depend on the time spent in their respective state.
In this model we will use a cycle duration of 1 year: we must take care that all transitions
probabilities, values attached to states, and discount rates are calculated on this time-frame.
We can now create the global parameters with define_parameters():
R> par_mod <- define_parameters(
R+ age_base = 20,
R+ age_cycle = model_time + age_base)
The age of individuals for a given cycle age_cycle is the age at the beginning of the model
(age_base), plus the time the model has run (model_time).
R> par_mod <- modify(
R+ par_mod,
R+
R+ sex_indiv = "MLE", # MLE => male in the WHO database
R+ p_death_all = get_who_mr(
R+ age = age_cycle,
R+ sex = sex_indiv,
R+ country = "GBR",
R+ local = TRUE))
The death probability p_death_all, as a function of age and sex, is fetched from the World
Health Organisation database with get_who_mr(),5 here for a British population.6
R> par_mod <- modify(
R+ par_mod,
R+
R+ p_death_disease = compute_surv(
R+ fit_death_disease,
4Or its alias markov_cycle.
5Relying on the rgho package (Filipovic-Pierucci 2017).
6We specify the use of local data cached in heemod with local = TRUE to avoid adding overhead query
time.
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R+ time = state_time,
R+ km_limit = 5))
The probability of dying of shame when the disease is symptomatic p_death_disease is ex-
tracted with the get_probs_from_surv() function from fit_death_disease, a model fitted
with the flexsurv package (Jackson 2016). Because this probability depends on time spent
in the disease state, the state_time model variable is used to specify time. Here we use
non-parametric Kaplan-Meier estimates for the first 5 years instead of model-fitted values
with km_limit = 5.
The parametric survival model fit_death_disease used to compute p_death_disease is
fitted with the following code:
R> fit_death_disease <- flexsurv::flexsurvreg(
R+ survival::Surv(time, status) ~ 1,
R+ dist = "weibull",
R+ data = tab_surv)
Where tab_surv is a data-frame containing survival data.
R> dput(tab_surv)
structure(list(time = c(0.4, 8.7, 7, 5.1, 9.2, 1, 0.5, 3.3, 1.8,
3, 6.7, 3.7, 1.1, 5.9, 5.1, 10, 10, 10, 10, 10, 10, 10, 10, 10,
10), status = c(1L, 1L, 1L, 1L, 1L, 1L, 1L, 1L, 1L, 1L, 1L, 1L,
1L, 1L, 1L, 0L, 0L, 0L, 0L, 0L, 0L, 0L, 0L, 0L, 0L)), .Names = c("time",
"status"), row.names = c(NA, -25L), class = "data.frame")
R> par_mod <- modify(
R+ par_mod,
R+
R+ p_death_symp = combine_probs(
R+ p_death_all,
R+ p_death_disease))
The death probability in the symptomatic state p_death_symp is the probability to die either
from old age (p_death_all) or from the disease (p_death_symp). Assuming those proba-
bilities are independent, we use the combine_probs() to combine them with the formula
P (A ∪B) = 1− (1− P (A))× (1− P (B)).
R> par_mod <- modify(
R+ par_mod,
R+
R+ p_disease_base = 0.25,
R+ med_effect = 0.5,
R+ p_disease_med = p_disease_base * med_effect)
The probability of disease under medical treatment p_disease_med is the base probability of
disease p_disease_base times the protecting effect of the treatment, med_effect.
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R> par_mod <- modify(
R+ par_mod,
R+
R+ shape = 1.5, # We will see later why we need
R+ scale = 5, # to define these 2 parameters here.
R+ p_disease_surg = define_survival(
R+ distribution = "weibull",
R+ shape = shape,
R+ scale = scale) %>%
R+ compute_surv(time = state_time))
The probability of disease after surgery is extracted with get_probs_from_surv() from a
parametric Weibull survival model defined with define_survival(). For reason explained
in Section 2.10 parameters scale and shape are not written in the define_survival() call,
but defined separately.
R> par_mod <- modify(
R+ par_mod,
R+
R+ cost_surg = 20000,
R+ cost_surg_cycle = ifelse(state_time == 1, cost_surg, 0))
Because surgery is only performed once at the beginning of the pre state, the time-dependant
variable state_time was used to limit surgery costs to the first cycle in the pre state.
R> par_mod <- modify(
R+ par_mod,
R+
R+ cost_hospit_start = 11000,
R+ cost_hospit_end = 9000,
R+ n_years = 9,
R+ cost_hospit_cycle = ifelse(
R+ state_time < n_years,
R+ cost_hospit_start,
R+ cost_hospit_end))
After n_years in the symptomatic state the symptoms become milder and hospital costs de-
crease (from cost_hospit_start to cost_hospit_end). We used the time-dependant vari-
able state_time to condition the hospital costs cost_hospit on n_years.
R> par_mod <- modify(
R+ par_mod,
R+
R+ p_cured = 0.001,
R+ cost_med = 5000,
R+ dr = 0.05,
R+ qaly_disease = 0.5)
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Figure 1: Transition diagram for the base strategy.
Finally we define p_cured the probability to spontaneously revert to the asymptomatic
unashamed state, cost_med the drug costs, dr the discount rate for a year and qaly_disease
the QALY for one year in the symptomatic state.
2.5. Transitions
We define a transition matrix for the base strategy with the define_transition() function.
We can reference parameters defined in the previous section.
R> mat_base <- define_transition(
R+ state_names = c("pre", "symp", "death"),
R+
R+ C, p_disease_base, p_death_all,
R+ p_cured, C, p_death_symp,
R+ 0, 0, 1)
R> mat_base
A transition matrix, 3 states.
pre symp death
pre C p_disease_base p_death_all
symp p_cured C p_death_symp
death 1
p_disease_base is the probability of being ashamed in the base strategy, p_death_all the all
cause probability of death (not caused by the disease) and p_death_symp the death probability
in the symptomatic state (greater than p_death_all). p_cured is the unlikely probability to
revert to the asymptomatic unashamed state. p_cured, p_death_symp and p_death_all do
not depend on the strategy. The value of these parameters will be defined later. C is an alias
for the probability complement, 1 minus the sum of probabilities in a given row. Death was
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modelled as an absorbing health state (i.e. the probability of transitioning from death to other
health states was set to zero). The resulting transition diagram is presented in Figure 1.7
Similarly, transitions can be defined for the other 2 strategies. In our case only the name
of the probabilities change: p_disease_base becomes p_disease_med or p_disease_surg
(those parameters will also be defined later).
R> mat_med <- define_transition(
R+ state_names = c("pre", "symp", "death"),
R+
R+ C, p_disease_med, p_death_all,
R+ p_cured, C, p_death_symp,
R+ 0, 0, 1)
R> mat_surg <- define_transition(
R+ state_names = c("pre", "symp", "death"),
R+
R+ C, p_disease_surg, p_death_all,
R+ p_cured, C, p_death_symp,
R+ 0, 0, 1)
2.6. State values
Next we define the values associated with states using the define_state function. An arbi-
trary number of values can be attached to a state, here we define: cost_treat the treatment
cost (drug costs for the med strategy or surgery costs for the surg strategy, there is no treat-
ment in the base strategy), cost_hospit the hospitalization costs, cost_total the total cost,
and qaly the health-related quality-adjusted life years (QALY), where 1 stands for one year
in perfect health and 0 stands for death (Torrance and Feeny 1989). In the following code we
define the state pre:
R> state_pre <- define_state(
R+ cost_treat = dispatch_strategy(
R+ base = 0, # no treatment => no treatment cost
R+ med = cost_med,
R+ surg = cost_surg_cycle),
R+ cost_hospit = 0, # good health => no hospital expenses
R+ cost_total = discount(cost_treat + cost_hospit, r = dr),
R+ qaly = 1)
To dispatch the cost of treatment according to the strategy we used the dispatch_strategy()
function, with arguments named as strategies (we will define the strategy names in Sec-
tion 2.8). Another approach would have been to define 3 versions of state_pre, one per strat-
egy, and in the next section use the corresponding version in each distinct define_strategy()
call.
7Generated by plot(mat_base).
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The total cost is discounted with the discount() function at a given rate (dr). The QALY
attached to 1 year in this state are set to 1, corresponding to 1 year in perfect health. The
variables dr, cost_med and cost_surg_cycle will be defined later.
The other 2 states are defined similarly:
R> state_symp <- define_state(
R+ cost_treat = 0,
R+ cost_hospit = cost_hospit_cycle,
R+ cost_total = discount(cost_treat + cost_hospit, r = dr),
R+ qaly = qaly_disease)
R> state_death <- define_state(
R+ cost_treat = 0,
R+ cost_hospit = 0,
R+ cost_total = 0,
R+ qaly = 0)
Patients have a degraded quality of life and are hospitalized during the symptomatic disease
phase, we need to define specific QALYs (qaly_disease) and hospital costs (cost_hospit_cycle)
for this state. These variables will be defined later. Finally dead patients have QALYs at 0,
and they do not cost anything to the healthcare system.
2.7. Strategies
All the information (states and transitions) is now available to define the strategies. For this
purpose we use the define_strategy() function. Only the transition objects differ between
strat_base, strat_med and strat_surg.
R> strat_base <- define_strategy(
R+ transition = mat_base,
R+
R+ pre = state_pre,
R+ symp = state_symp,
R+ death = state_death)
R> strat_med <- define_strategy(
R+ transition = mat_med,
R+
R+ pre = state_pre,
R+ symp = state_symp,
R+ death = state_death)
R> strat_surg <- define_strategy(
R+ transition = mat_surg,
R+
R+ pre = state_pre,
R+ symp = state_symp,
R+ death = state_death)
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2.8. Running the model
The model can then be run with run_model():
R> res_mod <- run_model(
R+ parameters = par_mod,
R+
R+ base = strat_base,
R+ med = strat_med,
R+ surg = strat_surg,
R+
R+ cycles = 10,
R+
R+ cost = cost_total,
R+ effect = qaly,
R+
R+ method = "life-table")
base: detected use of 'state_time', expanding states: pre, symp.
Fetching mortality data from package cached data.
Using cached data from year 2015.
Fetching mortality data from package cached data.
Using cached data from year 2015.
med: detected use of 'state_time', expanding states: pre, symp.
surg: detected use of 'state_time', expanding states: pre, symp.
Strategy names are defined at that point by using the argument names provided by the user.8
We define cost_total and qaly as the respective cost and effectiveness result. The model is
run for 10 cycles (i.e. 10 years), and state membership counts are corrected using the life-table
method (Barendregt 2009). By default the starting population is made of 1,000 patients in
the first state, and no patient in the other states.
8Strategy names are used in the results, and by functions such as dispatch_strategy().
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Figure 2: Incremental cost and effect of strategies on the cost-effectiveness plane, taking the
base strategy as a reference.
2.9. Results interpretation
How do the strategies compare to each other with regard to their relative cost and effectiveness?
The answer is given by calculating the total expected cost and effectiveness of all strategies,
and then computing the incremental cost-effectiveness ratio (ICER) between them (Drum-
mond et al. 2005). The ICER between strategies A and B is defined as:
CB − CA
EB − EA
Where C is the total expected cost of a strategy and E its total expected effect (e.g. sum of
life-years of the population). Thus the ICER is the cost of an incremental unit of effectiveness.
The most cost-effective strategy is (1) the most effective strategy (2) among the strategies
having an ICER no higher than a threshold. This ICER threshold is the maximal willingness
to pay for an additional unit of effectiveness: it is a political choice that depends on multiple
factors (Claxton et al. 2015).
The strategies can be presented on a cost-effectiveness plane (Figure 2),9 were we see that
both med and surg are more effective than base, but more costly.
R> summary(res_mod, threshold = c(1000, 5000, 15000))
3 strategies run for 10 cycles.
Initial state counts:
pre = 1000L
9Generated by plot(res_mod, type = "ce").
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symp = 0L
death = 0L
Counting method: 'life-table'.
Values:
cost_treat cost_hospit cost_total qaly
base 0 54214446 42615142 5792.258
med 27619456 37181168 52246211 7224.085
surg 10074777 47429243 46220058 6553.701
Net monetary benefit difference:
1000 5000 15000
1 8199.241 2471.932 0.000
2 5355.769 2674.230 7816.725
3 0.000 0.000 11846.341
Efficiency frontier:
base -> surg -> med
Differences:
Cost Diff. Effect Diff. ICER Ref.
surg 3604.915 0.7614427 4734.322 base
med 6026.153 0.6703846 8989.098 surg
From the printed model output presented above we see in the ICER column of the Differences
section that surg is more cost-effective than base if one is willing to pay 4,734 more per QALY
gained. Furthermore med is more cost-effective than surg if one is willing to pay 8,989 more
per QALY gained.
A net monetary benefit analysis (Stinnett and Mullahy 1998) is run by specifying thresholds
ICER values in the summary() function with the threshold argument. We see in the Net
monetary benefit section that at a threshold ICER of 1,000 the strategy with the highest
net monetary benefit is base, at 5,000 surg and at 15,000 med.
Figure 3 gives us more information about what happens in our model: the effect of surgery
seems to wear down with time compared to the medical treatment.10 Surgery delays the
outcome, reporting degraded health status and hospital costs further in time. After a few
years the hospital costs of the surgery strategy reach similar levels to the base strategy.
Nevertheless these increased hospital costs do not outweigh the important treatment costs
associated with the medical therapy.
10Generated by plot(res_mod, type = "counts", panel = "by_state") and plot(res_mod, type =
"values", panel = "by_value").
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2.10. Uncertainty analysis
What is the uncertainty of these results? What strategy is probably the most cost-effective?
Uncertainty of the results originate from uncertainty regarding the true value of the input
parameters (e.g. treatment effect, cost of hospital stays, quality of life with the disease,
survival probabilities). The effect of this uncertainty can be assessed by varying the parameter
values and computing the model results with these new inputs. While multiple methods exist
to study uncertainty (Briggs et al. 1994), deterministic and probabilistic sensitivity analysis
(DSA and PSA) are the most widely used (Briggs et al. 2006).
In a DSA, parameter values are changed one by one, usually to a low and high value (e.g. the
lower and upper bounds of the parameter confidence interval). Model results are plotted on a
tornado plot to display how a change in the value of one parameter impacts the model results.
A DSA gives a good sense of the relative impact of each parameter on the uncertainty of the
model outcomes, but does not account for the total uncertainty over all the parameters, for
skewed or complex parameter distribution, nor for correlations between the errors of different
parameter estimates (Briggs et al. 1994).
We define the DSA with define_dsa() by specifying a lower and upper bound for each
parameter of interest.
R> def_dsa <- define_dsa(
R+ age_base, 15, 30,
R+ p_disease_base, 0.2, 0.3,
R+ p_cured, 0.005, 0.02,
R+ med_effect, 0.3, 0.7,
R+ shape, 1.4, 1.6,
R+ scale, 4, 6,
R+ cost_med, 4000, 6000,
R+ cost_surg, 8000, 12000,
R+ cost_hospit_start, 5000, 15000,
R+ dr, 0, 0.1,
R+ qaly_disease, 0.3, 0.7,
R+ n_years, 8, 10)
R> res_dsa <- run_dsa(res_mod, dsa = def_dsa)
Running DSA on strategy 'base'...
Running DSA on strategy 'med'...
Running DSA on strategy 'surg'...
Only parameters (e.g. state values, transition probabilities) defined with define_parameters()
can be modified in a DSA (or a PSA). Accordingly, many state values, transition probabil-
ities, and the shape and scale parameters used in our example were defined as parameters,
thus allowing them to be varied in sensitivity analyses. Once defined, the analysis can be run
using run_dsa().
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3015
5000 15000
4000 6000
120008000
0.1 0
0.3 0.7
8 10
0.02 0.005
0.2 0.3
0.30.7
46
1.41.6
med
40000 50000 60000
cost_surg
qaly_disease
scale
shape
age_base
n_years
p_cured
p_disease_base
med_effect
cost_med
dr
cost_hospit_start
Cost
Va
ria
bl
e
Figure 4: Tornado plot presenting uncertainty of the cost for the med strategy. Each line
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Figure 5: Uncertainty of the incremental cost and effect of strategies on the cost-effectiveness
plane, taking the base strategy as a reference.
Figure 4 shows the impact of varying each parameter individually on total cost for the med
strategy.11 The results demonstrate that the discount rate and hospital costs have a greater
impact than other parameters. Unsurprisingly parameters used only in the surgery strategy
and parameters unrelated to costs have no effect on the cost of the med strategy.
In a PSA, the model is re-run for a given number of simulations with each parameter being re-
placed with a value re-sampled from a user-defined probability distribution. These results are
then aggregated, allowing us to obtain the probability distribution of model outputs (Critch-
field et al. 1986).
We define the parameter distributions with define_psa(), and optionally their correlation
structure with define_correlation().
R> def_psa <- define_psa(
R+ age_base ~ normal(mean = 20, sd = 5),
R+ p_disease_base ~ binomial(prob = 0.25, size = 500),
R+ p_cured ~ binomial(prob = 0.001, size = 500),
R+ med_effect ~ lognormal(mean = 0.5, sd = 0.1),
R+ shape ~ normal(mean = 1.5, sd = 0.2),
R+ scale ~ normal(mean = 5, sd = 1),
R+ cost_med ~ gamma(mean = 5000, sd = 1000),
R+ cost_surg ~ gamma(mean = 20000, sd = 3000),
R+ cost_hospit_start ~ gamma(mean = 11000, sd = 2000),
R+ dr ~ binomial(prob = 0.05, size = 100),
R+ qaly_disease ~ normal(mean = 0.5, sd = 0.1),
11Generated by plot(res_dsa, result = "cost", strategy = "med").
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R+ n_years ~ poisson(mean = 9),
R+
R+ correlation = define_correlation(
R+ shape, scale, -0.5,
R+ age_base, p_disease_base, 0.3))
R> res_psa <- run_psa(res_mod, psa = def_psa, N = 1000)
Resampling strategy 'base'...
Resampling strategy 'med'...
Resampling strategy 'surg'...
We then run the PSA with run_psa(), here for 1,000 re-samplings. The results can be plotted
as uncertainty clouds on the cost-effectiveness plane (Figure 5).12
The probability of a strategy being cost effective can be plotted for various willingness to
pay values on a cost-effectiveness acceptability curve (Van Hout et al. 1994; Fenwick and
Byford 2005). In Figure 6A we see that with a threshold ICER below 1,000 the base strategy
is probably the most cost-effective.13 Above 50,000, med is probably the most cost-effective
strategy. Between those 2 values the decision is less clear.
It is possible to compute the expected value of perfect information (EVPI) depending on the
willingness to pay (Claxton and Posnett 1996; Felli and Hazen 1997). This is a quantification
of the cost of potentially choosing the wrong strategy, and thus conversely the price one is
ready to pay to reduce the risk of incorrect decisions by obtaining more information (e.g. by
conducting more studies). In Figure 6B we see the EVPI peaks between 1,000 and 10,000,
where the uncertainty is high.14 It also increases for higher willingness to pay, because even
though the uncertainty is not as high, the costs of a wrong decision become higher.
The EVPI can indicate whether conducting more research is cost-effective. But it does not
inform on the value of getting more information on particular parameters (Briggs et al. 2006).
The expected value of perfect information for parameters (EVPPI) is very similar to the EVPI,
but returns values by parameters (Ades et al. 2004). Unfortunately its computation is not
trivial. PSA results can be exported to compute EVPPI with the Sheffield Accelerated Value
of Information SAVI software (Strong et al. 2014) with export_savi().
The individual contribution of parameter uncertainty on the overall uncertainty (Briggs et al.
2006) is illustrated by Figure 6C.15 We can see that, depending on the strategy, different
parameters generate the uncertainty on costs and effect. In all cases dr, cost_hospit_start
and qaly_disease explain a high part of variability for all strategies. Unsurprisingly the
effect of scale (the scale of the post-surgery Weibull survival function), med_effect and
cost_med are limited to the surg or med strategies.
12A similar plot can be generated with plot(res_psa, type = "ce").
13Generated by plot(res_psa, type = "ac").
14Generated by plot(res_psa, type = "evpi").
15Generated by plot(res_psa, type = "cov"). We could also perform the same analysis on the difference
between strategies with the option diff = TRUE.
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Figure 6: A: Cost-effectiveness acceptability curve; B: Expected value of perfect information;
C: Covariance analysis of PSA results.
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Figure 7: Heterogeneity of strategy effects in the population.
In addition, average model values can be computed on the results and presented in a summary
similar to the run_model() output. Because of non-linearities in Markov models, averages
over the PSA output distribution are more accurate than point estimates (Briggs et al. 2006).
In our case the ICERs changed from 4,734 to 6,453 and 8,989 to 7,059 for the surg and med
strategies respectively.
2.11. Heterogeneity analysis
How does the cost-effectiveness of strategies vary depending on the characteristics of the pop-
ulation?
If population characteristics are available, model results can be computed on the different sub-
populations to study the heterogeneity of the resulting model outputs (Briggs et al. 2006).
Furthermore, average population-level results can be computed from these distributions.
The model we ran in Section 2.9 computed results for a cohort of males aged 20. To assess
how population characteristics affect model results we can run a heterogeneity analysis. We
use the update() function to run the model on a table containing population data.16
R> head(tab_pop)
age_base sex_indiv .weights
1 10 MLE 0.04242889
2 10 FMLE 0.86696571
3 15 MLE 0.69960873
4 15 FMLE 0.51253057
16In this example we use a table with population characteristics, here named tab_pop, with an optional
column .weights giving the relative population weight of each strata.
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5 20 MLE 0.91723545
6 20 FMLE 0.09685623
R> pop_mod <- update(res_mod, newdata = tab_pop)
Updating strategy 'base'...
Updating strategy 'med'...
Updating strategy 'surg'...
The summary of the updated model gives the distribution of the values of interest in the
population, and the average model values over the entire population. Here the average ICERs
in the population are 5,052 and 9,150 for the surg and med strategies respectively, quite similar
to the values computed in Section 2.9 (4,734 and 8,989). We can also plot the distribution of
model results (e.g. the intervention effects in Figure 7).17
2.12. Budget impact analysis
What would be the total cost of a strategy for the health system?
So far we mostly worked on model results at the scale of the individual (e.g. cost per person).
If we want to implement a strategy at a health system level we also need to know the total
cost over a given time horizon, in order to assess whether the strategy is sustainable. This is
called a budget impact analysis (BIA). The main differences with the classic model are (1) the
patient counts at the model start should reflect the population statistics, and (2) additional
patients may enter the model every year (new disease cases).
We use the init and inflow arguments of run_model() to implement BIA, here for the med
strategy. The inflow of new patients is defined with define_inflow(). Inflow counts can
depend on model time (state time dependency is meaningless in this context).
R> res_bia <- run_model(
R+ parameters = par_mod,
R+
R+ med = strat_med,
R+
R+ cycles = 10,
R+
R+ cost = cost_total,
R+ effect = qaly,
R+
R+ method = "life-table",
R+
R+ init = c(
R+ pre = 25000,
R+ symp = 5000,
17Generated by plot(pop_mod, result = "effect", bins = 15).
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R+ death = 0),
R+ inflow = define_inflow(
R+ pre = 8000,
R+ symp = 0,
R+ death = 0))
med: detected use of 'state_time', expanding states: pre, symp.
At the start of the model there are 25,000 patients with asymptomatic shame and 5,000 with
a symptomatic form of the disease in the population. Every year 8,000 additional cases of
shame are added to the model, starting the disease in the asymptomatic state.
R> summary(res_bia)
1 strategy run for 10 cycles.
Initial state counts:
pre = 25000
symp = 5000
death = 0
Counting method: 'life-table'.
Values:
cost_treat cost_hospit cost_total qaly
med 1942366603 2621681008 3531335211 508495.2
The total cost of strategy med over a 10-year time horizon will be 3.5 billions.
3. Other features and extensions
This section introduces features and extensions that were not presented in the previous ex-
ample.
3.1. Survival analysis
The heemod package provides a number of ways to estimate transition probabilities from
survival distributions. Survival distributions can come from at least three different sources:
• User-definded parametric distributions created using the define_survival() function.
• Fitted parametric distributions with flexsurv::flexsurvreg() (Jackson 2016).
• Fitted Kaplan-Meiers with survival::survfit() (Therneau 2015; Therneau and Gramb-
sch 2000).
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Once defined, each of these types of distributions can be combined and modified using a
standard set of operations. Treatment effects can be applied to any survival distribution:
• Hazard ratio: apply_hr().
• Odds ratio: apply_or().
• Acceleration factor: apply_af().
In addition, distributions can be combined:
• Join one (or more) survival distributions together: join().
• Pool two (or more) survival distributions: pool().
• Combine two (or more) survival distributions as independent risks: add_hazards().
The transition or survival probabilities are computed with compute_surv(). Time (usually
model_time or state_time) needs to be passed to the function as a time argument.
All these operations can be chained with the %>% piping operator (Bache and Wickham 2014),
e.g.:
R> fit_cov %>%
R+ apply_hr(hr = 2) %>%
R+ join(
R+ fitcov_poor,
R+ at = 3) %>%
R+ pool(
R+ fitcov_medium,
R+ weights = c(0.25, 0.75)) %>%
R+ add_hazards(
R+ fit_w) %>%
R+ compute_surv(time = 1:5)
3.2. Convenience functions
For reproducibility and ease of use we implemented convenience functions to perform some of
the most common calculations needed in health economic evaluation studies (e.g converting
incidence rates, odds ratios, or relative risks to transition probabilities with rate_to_prob(),
or_to_prob(), or rr_to_prob() respectively). Probabilities and discount rates can be rescaled
to fit different time frames (generally the duration of a cycle) with rescale_prob() and
rescale_discount_rate().
3.3. Cluster computing
PSA and heterogeneity analyses can become time-consuming since they consist in iteratively
re-running the model with new parameter inputs. Because this workload is embarrassingly
parallel (Herlihy and Shavit 2012), i.e. there is no dependency or need for communication
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between the parallel tasks, it can easily be run on a cluster relying on the parallel (R Core
Team 2016) package. This is done by calling the use_cluster() function. This function can
either take as an argument:
1. A number: a local cluster with the given number of cores will be created.
2. A cluster object defined with the makeCluster() function from parallel: the user-
defined cluster will be used (e.g. to use more complex clusters with non-local hosts).
3.4. Alternative interfaces
To facilitate the use of heemod by users not familiar with R we developed a shiny (Chang
et al. 2017) graphical user interface. Similarly, for users that require the use of spreadsheet
models (such as health regulatory agencies), a model can be specified in spreadsheet files
and run by heemod. To keep the traceability, transparency and reproducibility advantages
provided by written source code it is possible to export models built from these interfaces to
R source code files.
These alternative interfaces are needed in a context where (1) Markov models are already
widely used and implemented on spreadsheet software, (2) a significant proportion of the
modellers are not R users, and (3) health regulatory agencies from several countries require
models to be in spreadsheet format. We believe that to gain acceptance in a field such as
health economic evaluation where habits are already ingrained one must adapt to existing user
requirements, as long as the final outcome is to help develop transparency and reproducibility
in the domain.
3.5. Extension to other types of model
Even though the main focus of heemod is to compute Markov models, other methods that
model state changes can be included in the package: only the transition argument of
define_strategy() and the associated evaluation methods need to be extended.
For example partitioned survival models (Williams et al. 2016b) were added to the package re-
cently. These models can be computed by passing an object defined by define_part_surv()
to transition.
In theory most modelling methods that return state counts over time could be integrated
into heemod, e.g. dynamic models for infectious diseases (Keeling and Rohani 2011; Snedecor
2012).
4. Mathematical implementation
In this section we detail the mathematical implementation of most of the features of heemod.
4.1. Parameter correlation in PSA
Correlation of parameters in PSA was implemented with the following steps:
1. A correlation structure is define with define_correlation() (see Section 2.10).
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2. Values are sampled from a multi-normal distribution having the required correlation
structure with mvnfast (Fasiolo 2016).
3. The sampled values are then mapped to the target distributions on a quantile by quantile
basis.
This approach described in Briggs et al. (2006) is an approximation that allows to define cor-
relations between arbitrary distributions. The final Pearson correlation coefficients between
the target distributions may differ slightly from the ones initially defined by the user. That
issue is mostly true if the target distributions are too dissimilar, e.g. a gamma and a binomial
distribution.
4.2. Time-dependency implementation
A throughout description of time-dependency in Markov models is given by Hawkins et al.
(2005), with solutions for the computation of both non-homogeneous and semi-Markov mod-
els. These methods were implemented in the heemod package. Markov models with model
time dependency are usually called non-homogeneous Markov models, and models with state
time dependency are called semi-Markov models.
Model time (non-homogeneous Markov models) was implemented by using a 3-dimensional
transition matrix U . As in the 2-dimensional matrix T described in Section 1 the indices of
the first 2 dimensions i, j encode the transition probability between state i and j. In addition
the third dimension index k corresponds to the number of cycles the model has run so far, so
that element i, j, k of matrix U corresponds to the transition probability between state i and
j at time k. The probability of being in a given state at time t is given by a simple extension
of Equation 1:
X ×
t∏
k=1
Uk (2)
Where X is a vector18 giving the probability of being in a given state at the start of the
model,
∏
stands for matrix multiplication, and Uk is a 2-dimensional slice of the 3-dimensional
transition matrix U , giving the transition probabilities at time k.
State time (semi-Markov models) was implemented with the tunnel-state method, described
in Hawkins et al. (2005). A tunnel state is a state that can be occupied for only 1 cycle, it
represents at the same time the health state a person is in and the number of cycles previously
spent in this state. A state A with state-time dependency is expanded in t tunnel states
A1, A2, . . . , At (where t is the total number of cycles). For example consider the following
transition matrix: [
P (A→ A) = f(s) P (A→ B) = C
P (B → A) P (B → B)
]
(3)
Where P (A → B) is the transition probability between state A and B, s the number of
cycles spent in state A, f an arbitrary function returning a transition probability, and C the
probability complement (1 minus the sum of probabilities in a given row). P (B → A) and
P (B → B) are arbitrary probabilities that do not depend on state time.
18Of length equal to the number of states.
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The matrix in Equation 3 can be expanded to the following matrix when the model is run for
t cycles: 
0 P (A1→A2)=f(1) 0 ··· 0 0 P (A1→B)=C
0 0 P (A2→A3)=f(2) ··· 0 0 P (A2→B)=C
0 0 0 ··· 0 0 P (A3→B)=C
...
...
...
. . .
...
...
...
0 0 0 ··· 0 P (At−1→At)=f(t−1) P (At−1→B)=C
0 0 0 ··· 0 P (At→At)=f(t) P (At→B)=C
P (B→A) 0 0 ··· 0 0 P (B→B)
 (4)
The semi-Markov model described in Equation 3 is now rearranged as a classic Markov model.
It can be noticed that if we were to run this model for more than t cycles then P (A → A)
would remain constant after time t, at a value of f(t). This property is useful in situations
where f(s) become roughly constant when s ≥ t: in that case we can stop the state expan-
sion at t tunnel states in order to limit the final matrix size, and thus the computational
burden. This approximation is implemented in heemod with the state_cycle_limit option
of run_model().
In practice in heemod any state where state time dependency is detected is implicitly converted
internally to a sequence of tunnel states. Counts and values are internally computed for each
tunnel state, and then internally re-aggregated before being returned to the user as a single
state. The transformation to a sequence of tunnel states is thus invisible for the user, except
for a message informing of the implicit state expansion.
4.3. Implementing budget impact analysis
The main technical difficulty to implement budget impact analyses is that new individuals
may enter the model at any point in time. The classic Markov model computation described
in Equation 1 cannot be used any more. Instead the probability of being in a given state at
time k is given by the following sequence:
a0 = Y
ak = ak−1 × T + Z
(5)
Where Y is a vector of the number of individuals in a given state at the start of the model,
T a 2-dimensional transition matrix, and Z a vector19 giving the number of new individuals
entering the model at each new cycle.
Equation 5 can be adapted to allow (1) for model time dependency of transition probabilities
as described in Equation 2 and (2) for time-dependency of the number of individual entering
the model at each new cycle, in this way:
a0 = Y
ak = ak−1 × Uk + Zk
(6)
Where Uk is a 2-dimensional slice of the 3-dimensional transition matrix U , and Zk a vector
giving the number of new individuals entering the model at cycle k.
Finally, state time dependency by tunnel state expansion can be integrated without any
change to Equation 6.
19Of length equal to the number of states.
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5. Package design and back-end
In this section we explain the ideas underlying the design of the package, the general struc-
ture, and the validation process. The entire workflow is summarised in a chart presented in
Figure 8. We then present the package back-end and how most of the features were actually
implemented.
5.1. Package design and workflow
The package was focused on reproducibility of analyses and ease of use. Both those objec-
tives could be reached by making the functions unambiguous and easily readable by humans.
We tried to rely on Hadley Wickham’s tidy manifesto to design our package in that direc-
tion (Wickham 2017).
We divided health economic evaluation modelling into distinct and sequential tasks, and
wrote simple verb functions corresponding to the most common tasks (e.g. define_*, run_*),
detailed in Figure 8.
We tried to keep functions as simple as possible: each function should do one thing, each
task should have its own function. By simplifying the options we hoped to simplify how
the user thinks about modelling, hence making it easier not only to build models, but more
importantly for another user to read and understand someone else’s model. This last point is
of particular importance if we want more research transparency and reproducibility in health
economic evaluation studies.
To paraphrase Hal Abelson, we think that models must be written for people to read, and
only incidentally for machines to execute.
5.2. Validation
We validated the package by reproducing the exact result of 2 analyses described in the
reference textbook by Briggs et al. (2006): the HIV therapy and the total hip replacement
model. In both case we found identical results (total values, patient counts and ICERs).
To ensure the results remain correct when the package is updated or when a dependency is
upgraded multiple tests were written with the testthat package (Wickham 2011). We verify
that functions produce the expected output, that incorrect inputs generate errors, and that
results from published models are reproduced. The tests are run as soon as a modification is
made to the code: when a change introduces a bug a warning is raised and remains until the
issue is fixed.
5.3. Back-end
The heemod package syntax relies heavily on the non-standard evaluation features offered
by lazyeval (Wickham 2016). This allows the user to define parameters, state values, and
transition probabilities as a sequence of expressions to be evaluated at runtime. In addition
to being familiar to users of the dplyr package (Wickham and Francois 2016), this results has
the advantage of resembling spreadsheet formulae and making heemod more approachable,
while keeping namespace collisions in check.20
20A usual pitfall of non-standard evaluation in R.
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Figure 8: heemod package workflow. Drawn with yEd (yWorks 2016).
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Figure 9: Example of plot customization.
More generally, most of heemod’s core functions rely on the dplyr package: the objects, data,
and results are stored as tbl_df objects, the dplyr implementation of data frames. This is
another principle of the tidy manifesto (Wickham 2017): reuse existing data structures. This
allows the use of powerful base functions, efficient computation by limiting copy creation,
and iterative model re-computation for PSA or heterogeneity analyses with the dplyr::do()
function.
Relying on another package instead of writing package-specific functions has the drawback
that slightly ill-fitting data structures may sometimes be used. But we think this drawback is
outweighed by the multiple advantages of piggybacking a widely used package such as dplyr.
We benefit from the code quality control and the constantly improving features of a popular
package, letting us focus our development time on actually implementing Markov models.
Even more importantly our internal code is easier to understand by anyone familiar with
dplyr. This last point reduces barriers to entry for potential contributors.
The plotting functions rely on the ggplot2 package (Wickham 2009), and can be easily cus-
tomized using the + operator. The following code is used to produce Figure 9:
R> library(ggplot2)
R+
R+ plot(res_psa, type = "ce") +
R+ scale_color_brewer(name = "Treatment", palette = "Set1") +
R+ facet_wrap(~ .strategy_names) +
R+ xlab("Incremental QALYs") + ylab("Incremental Costs") +
R+ geom_hline(yintercept = 0, linetype = "dashed") +
R+ geom_vline(xintercept = 0, linetype = "dashed")
The plotting of transition matrices as directed diagrams is performed by the diagram pack-
age (Soetaert 2014), the covariance analysis of PSA relies on the mgcv package (Wood 2011),
and the weighted summary of the results is computed with the Hmisc package (Harrell and
Dupont 2016).
The running time of some functions is not negligible (e.g. get_who_mr()). While half a
second is not an issue when a function is run only once, it becomes a major hurdle during
re-sampling where the function may be called thousands of times. We used the memoisation
features of the memoise package (Wickham et al. 2016) to shorten execution time: when a
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function is called the result is kept in memory alongside the values of the calling arguments.
If the function is called again with the same argument values then the function body is not
evaluated, but the memoised result is instantly returned instead. The use of memoisation is
particularly efficient in re-sampling because in most cases the values of the arguments of most
functions remain identical, resulting in the same outputs.
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